glp-1 latest How medications are transforming diabetes and weight loss treatment Poll: 1 in 8 Adults

Stroke and GLP-1RA Putative mechanisms linking GLP-1R activation to reduced rates of stroke are still emerging but are likely multifactorial with indirect effects on platelet aggregation

Both semaglutide and tirzepatide are well-known for their effects on weight loss and blood sugar control, but our study suggests they may also offer substantial benefits to patients with obesity and type 2 diabetes by reducing adverse heart failure outcomes. Despite promising results from existing randomized controlled trials of semaglutide and tirzepatide in those with obesity-related HFpEF, regulatory authorities and professional societies have not approved or endorsed the use of these drugs for HFpEF, due in part to the studies relatively small sample sizes and unknown generalizability

Therefore, FAS inhibition reduces hepatic steatosis and de novo lipogenesis [44]

Chronic Disease Management: Increased use of GLP-1 medications may reduce the incidence of diabetes-related hospitalizations by 10%15% and cardiovascular events by up to 20%, improving long-term population health outcomes

Semaglutide works by mimicking a hormone called GLP-1 (glucagon-like peptide-1), which helps regulate blood sugar levels and appetite

Stanford reports research funding from the National Institutes of Health